The authors concluded that a combination of mTOR inhibitor temsirolimus dosed at 115 mg weekly and AKT inhibitor perifosine dosed at 100 mg daily (following a loading dose of 600 mg) is tolerable in heavily pretreated patients with recurrence of malignant gliomas, including rGBM. Here, MTOR is linked to malignant glioma.